Evaluation the efficacy of olibanum gum in Alzheimer disease

Evaluation the efficacy of olibanum gum in cognitive impairment of patients with mild to moderate Alzheimer disease compared to placebo

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017060918951N3

Enrollment

120

Registered

2017-08-19

Start date

2017-09-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease. Alzheimer disease

Interventions

Intervention 1: Intervention: Olibanum gum, Three time in day. Intervention 2: Control: Simple gum, Three time in day.

Treatment - Drugs

Intervention: Olibanum gum, Three time in day

Control: Simple gum, Three time in day

Eligibility

Sex/Gender

All

Age

60 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Mild to moderate Alzheimer disease patients based on MMSE Scale. Exclusion criteria: Major depression; Sever internal disease; Ischemic heart disease; Uncontrolled hypertension; Uncontrolled diabetes ;Drug and alcohol abuse.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cognitive function. Timepoint: Weeks of 0, 4, 8, 16, 18. Method of measurement: Mini Mental State Exam (MMSE).	—

Secondary

Measure	Time frame
Memory. Timepoint: Weeks of 0, 4, 8, 12, 16, 18. Method of measurement: W.M.S scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereshteh Ghorat

Scientific Association of Traditional Medicine

drghorat@gmail.com+98 21 8897 6528

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026